Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
about
Adjuvant Therapy for completely resected Stage II Colon CancerAdjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled studyIdentification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytesBiological response modifiers in cancerRole of Toll-like receptors in adjuvant-augmented immune therapies.Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.Immunotherapy in human colorectal cancer: Challenges and prospectiveTumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer modelIs cancer vaccination feasible at older age?Combination of physical activity, nutrition, or other metabolic factors and vaccine responseToll-like receptor agonists in cancer therapy.Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.Strategies for cancer vaccine development.Immunotherapy: on the edge between experimental and clinical oncology.Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancerA randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.Science, medicine, and the future: Cellular immunotherapy for cancer.Translating tumor antigens into cancer vaccinesTumor vaccine against recurrence of hepatocellular carcinoma.Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human gliomaRecent advances in cancer vaccines: an overview.Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils.Overview of the clinical efficacy of investigational anticancer drugs.Dimerumic acid inhibits SW620 cell invasion by attenuating H₂O₂-mediated MMP-7 expression via JNK/C-Jun and ERK/C-Fos activation in an AP-1-dependent manner.Randomized controlled trials in colorectal disease; a review of recent trials.Current status of autologous breast tumor cell-based vaccines.Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.Cellular vaccine therapy for cancer.Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Aluminum nanoparticles enhance anticancer immune response induced by tumor cell vaccineTherapeutic vaccines for gastrointestinal cancers.Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor?Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Glycan array analysis of the antigen repertoire targeted by tumor-binding antibodies
P2860
Q24242231-FB5E3153-D46C-43AC-81AC-96668B65CE68Q24645666-174EEDA4-0CC0-4262-927D-65AD376EF440Q24649346-EF011196-2C0E-490B-B06D-D3961EDC0DA0Q24685049-F0388D7D-2428-43F5-9969-5131449AF31FQ25257661-75A82E28-6393-4824-84AB-574EE7AAEAECQ27323878-713688E7-02DC-4123-9C0C-44466FCA5B83Q28068788-376914D4-F339-42D7-A870-7EBDDA4A80DEQ33552813-3F63B798-EF4A-4506-AAEC-2528809A0475Q33689002-B7BF4EFB-CCCC-4E91-82D2-99967AB2AE3FQ33739907-392A4753-E59F-47F1-81F3-1CB365EE3295Q33751144-839C8E59-8893-45A8-AB1B-23E0C767F5EAQ33918509-05BD4AA9-2CF6-4365-8324-46413E13F991Q33997622-98B8B470-E761-446A-8F2B-5F857A184540Q34038338-CC9C5F05-289C-448A-A5A6-528B321BDA84Q34172095-FB7DCE5D-9EDB-4139-8FC2-0D9FB06197EBQ34291851-76207BD7-212A-4091-BDAD-6DA6B0D85C89Q34365990-C5E62801-892D-4D8F-B716-4EB5F1866AAEQ34434814-D5FA3F3F-9051-4BCC-AFEE-9E66B5064E1DQ34455397-AA991089-12EF-4527-8A64-48B727D1400EQ34484042-F46E6084-70AF-41EA-A837-4FCC6BC1B04DQ34605421-2815507F-B41D-4CA5-A57D-A8C5CE229E1BQ34657329-2589B21F-0ABE-47FB-9429-D6033BCA35B9Q34882348-37FFD7FE-57AD-4D05-8E09-DC34162BC44CQ34956634-A0F7AA44-1E13-43A0-AAE1-5081CEC1F15AQ35067125-2EFCAC4E-4BBD-4362-AF49-C41AAEDF8103Q35144719-A202B04A-B6B6-40B7-B364-BACE9352BAFEQ35147238-3328B791-0922-43DF-8064-6E3F69B49207Q35154214-D0638C02-536F-4772-ABA9-D29310B005B8Q35160569-AB7BE447-93D1-45F1-8DCC-34E454FFBCC3Q35193459-19846304-C4F8-492F-9C4E-2371994BA985Q35294382-927EA57F-D49D-4853-AECB-67F436575A05Q35584153-F81A43AD-2EC1-4350-93CD-3FAC361C5714Q35672984-B9EC6819-CADD-420E-9428-6132EC34752CQ35691248-A810E0E4-839D-423E-A66A-6811D8FDAEAAQ35878440-9A2B4D44-F99E-4967-9A35-6DA3640A2BD8Q36055257-D5957A47-D84D-44A8-9C56-3A7366FD6FB0Q36114649-E30F704E-ADFB-41DD-8BEC-C1302823F592Q36255729-87DD67E3-3CED-46BF-8566-73A3E0FB6FEBQ36269694-B997A4D3-3426-444F-A1A2-7DDEA8537383Q36340501-6B4B90BC-6502-4C83-AEA0-FC54490AE9A3
P2860
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Active specific immunotherapy ...... on cancer: a randomised trial.
@ast
Active specific immunotherapy ...... on cancer: a randomised trial.
@en
Active specific immunotherapy ...... on cancer: a randomised trial.
@nl
type
label
Active specific immunotherapy ...... on cancer: a randomised trial.
@ast
Active specific immunotherapy ...... on cancer: a randomised trial.
@en
Active specific immunotherapy ...... on cancer: a randomised trial.
@nl
prefLabel
Active specific immunotherapy ...... on cancer: a randomised trial.
@ast
Active specific immunotherapy ...... on cancer: a randomised trial.
@en
Active specific immunotherapy ...... on cancer: a randomised trial.
@nl
P2093
P1433
P1476
Active specific immunotherapy ...... on cancer: a randomised trial.
@en
P2093
A M Claessen
C J Meijer
E Bloemena
H M Pinedo
H van Tinteren
J B Vermorken
J H Ransom
P304
P356
10.1016/S0140-6736(98)07186-4
P407
P577
1999-01-01T00:00:00Z